Unigene & GSK Ink Pact for the Treatment of Osteoporosis in Postmenopausal Women

Unigene will receive up to approximately $2.2 million in milestone payments from GSK to undertake certain development and manufacturing activities.

Biopharmaceutical company Unigene Laboratories, Inc. announced Monday the Company has signed a Development Services and Clinical Supply Agreement with GlaxoSmithKline.

Under the terms of the agreement, Unigene will receive up to approximately $2.2 million in milestone payments from GSK to undertake certain development and manufacturing activities. These activities are related to the active pharmaceutical ingredient and finished drug product for an oral formulation of a recombinantly produced investigational parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women in advance of GSK's potential decision to study the molecule in a Phase 3 program.

Unigene is developing its investigational oral PTH in collaboration with GSK as p